Rosinha Alina, Rabaça Carlos, Calais Fernando, Pinto João Moreira, Barreira João Vasco, Fernandes Ricardo, Ramos Rodrigo, Fialho Ana Cristina, Palma Dos Reis José
Oncology Department, Portuguese Institute of Oncology (IPO) Porto, Porto, Portugal.
Urology Department, Portuguese Institute of Oncology (IPO) Coimbra, Coimbra, Portugal.
Front Oncol. 2024 Jan 23;13:1266369. doi: 10.3389/fonc.2023.1266369. eCollection 2023.
Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.
非转移性去势抵抗性前列腺癌（nmCRPC）是前列腺癌治疗中一种具有挑战性的疾病状态。通过前列腺特异性抗原倍增时间（PSADT）≤10个月确定有进展为转移性疾病高风险的nmCRPC患者，有资格接受新型雄激素受体抑制剂（ARIs）治疗，已证明该治疗可延缓疾病进展并延长生存期。然而，由于nmCRPC识别方法和工具缺乏标准化，在临床实践中其往往未得到充分利用。在本文中，一组在前列腺癌方面具有公认专业知识的泌尿外科和肿瘤学专家回顾了高危nmCRPC患者管理的最新进展，确定了差距和未满足的需求，并提出了在临床实践中优化该患者亚组识别并改善其健康结局的策略。
